PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 21/03/2025			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

30/24/30	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/24/30	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	1.68TCr 1.17Cr 1.02Cr 94.59L 86.85L 1.64Cr 111.6Cr 1.67Cr 11Cr 4.38Cr 56Cr 4.39Cr 4.29Cr 186.3Cr	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	2.38TCr 1.66Cr 1.44Cr 1.34Cr 1.23Cr 2.33Cr 158.29Cr 2.36Cr 16Cr 6.21Cr 79Cr 6.23Cr 6.09Cr 264.25Cr	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

30/24/30	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/24/30	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
22/24/22	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
25/24/25	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
21/24/21	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
16/24/16	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
26/23/26	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
21/23/21	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
15/23/15	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
31/23/31	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
31/23/31	PCL to Raise 36 Billion Won via Share Issuance	MT
23/23/23	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
29/22/29	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	94,500
5 years	5,900	3,52,666.67
10 years	5,900	5,23,333.33

PCL, Inc. Share Price

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news : PCL, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	28/03/2024
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	28/03/2024

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	73	-
Mu-Yong So BRD	Director/Board Member	53	28/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-88.11%	1.17Cr
VERACYTE, INC.	-22.52%	-18.18%	+95.94%	+79.19%	372.37Cr
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-6.66%	+1.35%	+118.49%	+183.54%	359Cr
CAREDX, INC.	+14.72%	+17.69%	+257.69%	+288.19%	226.13Cr
BGI GENOMICS CO., LTD.	+3.44%	+4.55%	-27.34%	-35.28%	216.85Cr
IOVANCE BIOTHERAPEUTICS, INC.	-13.22%	-18.44%	+51.87%	-43.31%	181.73Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	-2.67%	-2.81%	+195.95%	-45.02%	97Cr
SEEGENE, INC.	+6.96%	-1.82%	-7.40%	+21.17%	85Cr
HANGZHOU ALLTEST BIOTECH CO., LTD.	+1.29%	+6.41%	-38.87%	-11.36%	51Cr
CURIOX BIOSYSTEMS CO., LTD	+7.90%	-3.22%	-0.27%	-	45Cr
Average	-1.24%	-2.92%	+64.61%	+38.78%	163.55Cr
Weighted average by Cap.	-5.11%	-3.72%	+95.62%	+89.14%

	2023	2024
Net sales	842.95Cr 58.65L 50.98L 47.45L 43.57L 82.27L 56Cr 83.55L 5.59Cr 2.2Cr 28Cr 2.2Cr 2.15Cr 93Cr	124.62Cr 9L 8L 7L 6L 12.16L 8.28Cr 12.35L 82.69L 32.45L 4.12Cr 32.56L 31.85L 14Cr
Net income	-2.03TCr -1.41Cr -1.23Cr -1.14Cr -1.05Cr -1.98Cr -134.94Cr -2.01Cr -13Cr -5.29Cr -67Cr -5.31Cr -5.19Cr -225.26Cr	-5.23TCr -3.64Cr -3.17Cr -2.95Cr -2.71Cr -5.11Cr -347.61Cr -5.19Cr -35Cr -14Cr -173.05Cr -14Cr -13Cr -580.27Cr
Net Debt	720.41Cr 50.12L 43.57L 40.55L 37.23L 70.31L 48Cr 71.4L 4.78Cr 1.88Cr 24Cr 1.88Cr 1.84Cr 80Cr	703.02Cr 48.91L 42.52L 39.58L 36.34L 68.62L 47Cr 69.68L 4.66Cr 1.83Cr 23Cr 1.84Cr 1.8Cr 78Cr